Drug target · KCNQ2
Kv7.2
Potassium voltage-gated channel subfamily Q member 2
2 compounds in the CNS pipeline act on Kv7.2.
Compounds targeting Kv7.2
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| Azetukalner (XEN1101)primarySmall molecule | Activator | EC50 27 nM | Phase 3Epilepsy | Xenon Pharmaceuticals Inc. |
| Opakalim (BHV-7000)primarySmall molecule | Activator | EC50 0.6 µM | Phase 3Epilepsy | Biohaven Ltd. |